A new Cochrane Review provides further confirmation of the benefits of different human papillomavirus (HPV) vaccines and vaccine schedules in adolescent women and men.
The Review summarised results from 20 randomised controlled trials involving 31,940 people conducted across all continents, given bivalent, quadrivalent or nonavalent HPV vaccines.
The length of follow‐up ranged from seven months to five years.
The immunogenicity of two‐dose and three‐dose HPV vaccine schedules, measured using antibody responses in young females, was comparable.
Antibody responses in both males and females were stronger when the interval between the first two doses of HPV vaccine was longer.
In young men, the quadrivalent HPV vaccine reduced incidence of external genital lesions and genital warts compared with controls.
The nonavalent and quadrivalent vaccines offered similar protection in young females against a combined outcome of cervical, vaginal, and vulval precancer lesions or cancer.
In people living with HIV, both the bivalent and quadrivalent HPV vaccines resulted in high antibody responses.
For all comparisons of alternative HPV vaccine schedules, the certainty of the body of evidence about serious adverse events reported during the study periods was low or very low, either because the number of events was low, or the evidence was indirect, or both.